**Breaking News!  China’s Cancer Drug Outperforms Global PD-1 Inhibitor!**

**Breaking News!  China’s Cancer Drug Outperforms Global PD-1 Inhibitor!**

PD1

#AK112 #CancerDrug #PD-1 #PD1Inhibitor #CancerTreatment #BispecificAntibody #NSCLC

China’s pharmaceutical industry has reached a historic milestone! Remember AK112 (Ivonescimab), which took center stage during this year’s ASCO conference, attracting global attention for its groundbreaking potential? The long wait is finally over, and the results are in!

In May, Akeso Biopharma, a leading Chinese pharmaceutical company, announced that its independently developed bispecific antibody drug AK112 achieved a major milestone in clinical trials. AK112 demonstrated superior efficacy to the globally renowned PD-1 inhibitor Keytruda (K Drug) in treating PD-L1-positive non-small cell lung cancer (NSCLC), marking a revolutionary breakthrough for China’s innovative cancer treatments.

**Clinical Data that Surprised the World**

During the World Conference on Lung Cancer 2024, Professor Zhou Caicun, one of China’s top lung cancer experts, revealed the results of the HARMONi-2 study, which had the entire audience applauding. The data exceeded expectations, demonstrating that AK112 is not just on par with but superior to international “superstar” cancer drugs in several key areas.

– **Progression-Free Survival (PFS):** AK112 improved PFS by an astonishing 91.4% compared to Keytruda, reaching 11.14 months versus 5.82 months.

– **Risk Reduction:** AK112 reduced the risk of disease progression or death by 49%.

– **Objective Response Rate (ORR):** AK112 outperformed Keytruda with a response rate of 50.0% compared to 38.5%.

– **Disease Control Rate (DCR):** AK112 maintained a significant advantage, achieving 89.9% versus 70.5%.

While AK112 showed slightly higher Grade 3 side effects due to its VEGF inhibition, its overall performance remains remarkable. Although overall survival (OS) data is still maturing, AK112’s impressive PFS results suggest that its survival benefits will likely be just as extraordinary.

**The Power of Bispecific Antibodies**

AK112 is part of a new class of cancer drugs called bispecific antibodies, capable of targeting two different antigens at once. In this case, AK112 targets both PD-1 and VEGF, two well-known lung cancer markers. This dual-target approach offers patients better therapeutic options and increased convenience, potentially replacing the traditional combination of PD-1 inhibitors with anti-angiogenic drugs like Avastin.

This breakthrough has made AK112 the first and only bispecific antibody drug to outperform Keytruda in head-to-head clinical trials, solidifying its place as a future game-changer in cancer treatment.

**A Milestone for China’s Pharma Industry**

In May 2024, AK112 received regulatory approval from China’s National Medical Products Administration (NMPA) for treating EGFR-mutated, locally advanced, or metastatic NSCLC, becoming the world’s first approved PD-1/VEGF bispecific antibody.

This marks a monumental achievement for China’s pharmaceutical innovation. AK112’s success demonstrates that Chinese researchers and drug developers, in just two decades, have achieved what took developed nations over a century. China’s presence at top-tier global cancer conferences like ASCO and ESMO has never been stronger, with clinical data that leaves the world in awe.

China’s pharmaceutical industry may have started late, but its rapid progress is a testament to the ingenuity and hard work of its researchers. Once relying on generics, China is now a leader in pharmaceutical innovation, offering cutting-edge treatments to patients around the globe. The future of cancer treatment is here, and it’s painted in the bold color of “China Red.”

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #MedicalInnovation #PharmaBreakthrough #ChinaPharma #AK112 #LungCancer #BispecificAntibody #PD1Inhibitor #GlobalHealth #MedicalAdvancements #ProudlyMadeInChina #WorldClass

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago Myeloma

**Treatment for Multiple Myeloma: China’s BCMA×CD3 Bispecific Antibody Proposed for Breakthrough Therapy Designation**

**Treatment for Multiple Myeloma: China’s BCMA×CD3 Bispecific Antibody Proposed for Breakthrough Therapy Designation**

Multiple Myeloma

#MultipleMyeloma #BCMAxCD3 #BispecificAntibody #Immunotherapy #GR1803 #NMPA #RRMM

Recently, GR1803, an injectable solution developed by Genrix Bio, has been proposed for the “Breakthrough Therapy Designation” by the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA). This innovative drug targets relapsed and refractory multiple myeloma (RRMM), especially for patients who have undergone at least three lines of treatment, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

GR1803 is a novel bispecific antibody that simultaneously binds to BCMA and CD3 antigens. Its unique design allows for the effective activation of T-cells to attack tumor cells while minimizing non-specific T-cell activation, reducing potential side effects. In its Phase I clinical trial for RRMM, GR1803 demonstrated an overall objective response rate (ORR) of 85%, with an ORR of 100% in patients with extramedullary plasmacytoma (EMM).

The clinical performance of this product is remarkable, as evidenced by data presented at the 2024 European Hematology Association (EHA) annual meeting. As of January 2024, 40 trial participants have been enrolled, with an ORR of 85%. Notably, in the 180 ug/kg dose group, the median follow-up duration was 15 weeks, and 96% of the patients achieved a significant response.

What’s particularly noteworthy is the rapid response time; patients showed signs of improvement within a median of just 3 weeks. This suggests that GR1803 not only provides effective disease control in the short term but also continues to enhance patients’ conditions as treatment progresses.

The results from Genrix Bio’s research highlight that GR1803 offers new hope for RRMM patients, particularly for those who are unresponsive to conventional therapies. Its high response rate and favorable safety profile suggest that this drug could play a critical role in future cancer treatments.

The development of such groundbreaking drugs and the advancement of breakthrough therapies reflect China’s growing innovation in the global fight against cancer, offering new treatment options for patients worldwide.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070  

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#MultipleMyeloma #CancerTreatment #BreakthroughTherapy #Immunotherapy #BiotechInnovation #GenrixBio #BCMAxCD3 #CancerResearch #OncologyNews #PharmaInnovation